 Kiniksa Pharmaceuticals Ltd NASDAQ: KNSA is trading lower Tuesday morning after the company announced the Phase 3 trial of mavrilimumab in COVID-19-related ARDS did not meet the primary efficacy endpoint. Mavrilimumab is an investigational fully human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha. 